Safety and Efficacy of Pegylated Interferon Therapy in Liver Cirrhosis Patients
Author Information
Author(s): Wang Zehong, Wang Xuanxuan, Zhou Li, Shi Shaoyuan, Hua Yongli, Feng Yinong
Primary Institution: Department of Hepatology, The Third People’s Hospital of Taiyuan, Taiyuan, Shanxi Province, China
Hypothesis
Can pegylated interferon-α-2b therapy improve outcomes in patients with hepatitis B virus-related compensated liver cirrhosis?
Conclusion
A finite course of PEG-IFN-α-2b therapy was well-tolerated and reduced HBsAg levels without accelerating disease progression in patients with HBV-related compensated cirrhosis.
Supporting Evidence
- 42 patients achieved undetectable serum HBV DNA at 48 weeks post-therapy.
- HBsAg level was significantly reduced at 48 weeks post-therapy.
- Three patients achieved HBsAg loss, and two obtained HBsAg seroconversion.
- No patients suffered from virological breakthrough or progressed to end-stage liver diseases during the observational period.
Takeaway
This study tested a medicine called PEG-IFN-α-2b on patients with liver problems from hepatitis B, and it helped lower a harmful substance in their blood without making their condition worse.
Methodology
This was a single-center, prospective, observational study where patients received PEG-IFN-α-2b therapy for 48 weeks, and various clinical and laboratory assessments were conducted.
Limitations
The study was limited by its small sample size and single-center design, and it only observed 48 weeks of treatment.
Participant Demographics
{"male_percentage":61.11,"mean_age":43.02,"treatment_naive_percentage":55.56,"nucleoside_analog_experienced_percentage":44.44}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website